Literature DB >> 18402507

Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.

Daniel Weintraub1, Cynthia L Comella, Stacy Horn.   

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disease associated with substantial morbidity, increased mortality, and high economic burden. Of importance to managed care is that the number of cases of PD are on the rise, paralleling the advancing age of the population, and misdiagnosis is common. Effective management of PD can minimize disability and potentially improve long-term outcomes, which would minimize long-term healthcare costs and medical resource utilization. This article provides a brief review of the epidemiology, pathophysiology, clinical course, and burden of PD.

Entities:  

Mesh:

Year:  2008        PMID: 18402507

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  66 in total

1.  CSF markers of neurodegeneration in Parkinson's disease.

Authors:  Hana Přikrylová Vranová; Jan Mareš; Martin Nevrlý; David Stejskal; Jana Zapletalová; Petr Hluštík; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2010-08-21       Impact factor: 3.575

2.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

Review 3.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

4.  The relationship between quality of life and swallowing in Parkinson's disease.

Authors:  Emily K Plowman-Prine; Christine M Sapienza; Michael S Okun; Stephenie L Pollock; Charles Jacobson; Sam S Wu; John C Rosenbek
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

5.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 6.  Differences between conventional and nonconventional MRI techniques in Parkinson's disease.

Authors:  A Baglieri; M A Marino; R Morabito; G Di Lorenzo; P Bramanti; S Marino
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

8.  DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.

Authors:  Chenere P Ramsey; Elpida Tsika; Harry Ischiropoulos; Benoit I Giasson
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

9.  Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.

Authors:  Maryam Rezaei; Masoud Alirezaei
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

10.  Epigenetics-Based Therapeutics for Neurodegenerative Disorders.

Authors:  Zihui Xu; He Li; Peng Jin
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.